Featured Research

from universities, journals, and other organizations

Potential Diagnostic Marker Indicates Effectiveness Of Anti-angiogenic Drugs

Date:
October 2, 2006
Source:
American Association for Cancer Research
Summary:
If an anti-angiogenic drug is successfully starving a cancer patient's tumor to death, the number of endothelial cells circulating in the individual's bloodstream will decrease, thus providing a potential biomarker for gauging the medication's effectiveness, according to National Cancer Institute research.

If an anti-angiogenic drug is successfully starving a cancer patient's tumor to death, the number of endothelial cells circulating in the individual's bloodstream will decrease, thus providing a potential biomarker for gauging the medication's effectiveness, according to National Cancer Institute (NCI) research.

Related Articles


Previous studies have shown that the blood circulation of cancer patients has an abnormally high number of endothelial cells, which help construct blood vessels including those that feed the cancerous tumor.

"For a cancer to survive, grow and spread, a tumor needs to make more endothelial cells and construct new blood vessels to provide oxygen and other nutrients," said NCI scientist Haiqing Li, Ph.D., first author of the study.

"In addition to growing them directly from nearby blood vessels, tumors can also signal the body's bone marrow to boost the supply of endothelial cells in the blood circulation," Li added.

Results were presented at the first international meeting on Molecular Diagnostics in Cancer Therapeutic Development, organized by the American Association for Cancer Research.

Anti-angiogenic drugs inhibit blood vessel development at the tumor by killing the endothelial cells lining tumor blood vessels and/or cutting off the supply of endothelial cells from bone marrow. These drugs are typically paired with chemotherapy agents. Unlike anti-angiogenic drugs, chemotherapy agents directly assault tumor cells, and a reliable therapeutic biomarker for evaluating these agents is whether there are fewer cells in the tumor, or more, or just the same amount as before the treatment. Some chemotherapy drugs, Li noted, also have the benefit of being toxic to endothelial cells, providing a possible second biomarker for those agents.

But biomarkers have yet to be defined for anti-angiogenic drugs. "Many anti-angiogenic drugs may encounter problems during clinical studies, because they can't reduce tumor size rapidly like chemotherapies can," noted Li. "Thus, a biomarker is needed for the effectiveness of anti-angiogenic drugs in an early stage."

The NCI study, conducted with the European Institute of Oncology (EIO), suggests that the anti-angiogenic drugs enhance chemotherapy's ability to kill endothelial cells, as indicated by increases in dead endothelial cells circulating in the patient's blood stream.

The NCI and EIO scientists also discovered that anti-angiogenic drugs might combat cancer by preventing immature cells in the bone marrow from developing into endothelial cells.

This research was conducted with four groups of immunodeficient mice in which human prostate cancer cells had been implanted. Each group received a different treatment: a control agent (no drug); a chemotherapy agent (docetaxel) only; an anti-angiogenic drug (thalidomide) alone; and both chemotherapy and the anti-angiogenic drugs.

Circulating endothelial cell (CEC) levels were measured before all four groups were treated and at specific times during the study. In the group receiving only chemotherapy, blood levels of dead CECs soon increased, up to 2.6 fold. In the animals treated with the two drugs, CEC death was higher -- up to 4.3 fold -- suggesting that the anti-angiogenic agent may have enhanced chemotherapy's ability to kill the tumor vascular endothelial cells.

Tests conducted later in the study revealed that treatment with the anti-angiogenic drug alone reduced the level of viable CECs by 18 percent, while treatment with only chemotherapy decreased it by 61 percent. The combination of both drugs further diminished the blood levels of viable CECs by 75 percent, indicating that the anti-angiogenic drug may have inhibited the immature endothelial cells in the bone marrow from reproducing and differentiating into adult cells.

Li is continuing her research on CECs in cancer. "We are in the process of testing whether this biomarker is exclusive for anti-angiogenic therapy," she added. "Hopefully, the knowledge we learn pre-clinically will be translated into a useful biomarker for patients."


Story Source:

The above story is based on materials provided by American Association for Cancer Research. Note: Materials may be edited for content and length.


Cite This Page:

American Association for Cancer Research. "Potential Diagnostic Marker Indicates Effectiveness Of Anti-angiogenic Drugs." ScienceDaily. ScienceDaily, 2 October 2006. <www.sciencedaily.com/releases/2006/09/060915202459.htm>.
American Association for Cancer Research. (2006, October 2). Potential Diagnostic Marker Indicates Effectiveness Of Anti-angiogenic Drugs. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/2006/09/060915202459.htm
American Association for Cancer Research. "Potential Diagnostic Marker Indicates Effectiveness Of Anti-angiogenic Drugs." ScienceDaily. www.sciencedaily.com/releases/2006/09/060915202459.htm (accessed October 25, 2014).

Share This



More Health & Medicine News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Doctor in NYC Quarantined With Ebola

Doctor in NYC Quarantined With Ebola

AP (Oct. 24, 2014) An emergency room doctor who recently returned to the city after treating Ebola patients in West Africa has tested positive for the virus. He's quarantined in a hospital. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins